Rady Children's Specialists of San Diego
Mount Sinai School of Medicine
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
Dermatology, Pediatric Dermatology, Pediatrics
Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine. He is board certified in dermatology, pediatric dermatology and pediatrics.
After earning his medical degree from Mount Sinai School of Medicine in New York, Dr. Eichenfield was a pediatric resident and chief resident at Children's Hospital of Philadelphia. He then completed his dermatology residency at the Hospital of the University of Pennsylvania.
Along with longstanding expertise in atopic dermatitis, acne, psoriasis and other inflammatory skin conditions, Dr. Eichenfield has interests in neonatal dermatology, vascular lesions, laser surgery and rare skin disorders. He has authored more than 400 journal articles, chapters, abstracts and books, and has served as the senior editor of "Neonatal and Infant Dermatology," published by Elsevier, as well as "The Eczemas." He served as editor-in-chief of Pediatric Dermatology for 12 years and currently serves on the editorial boards of multiple journals and periodicals.
Dr. Eichenfield has held multiple leadership positions, including co-founder and co-chair of the Pediatric Dermatology Research Alliance, co-chair of the American Academy of Dermatology Guidelines for Atopic Dermatitis, co-chair of the American Acne and Rosacea Society/American Academy of Pediatrics Pediatric Acne Recommendations for Diagnosis and Treatment, member of the Expert Panel Member of the NIAID Guidelines for Diagnosis and Management of Food Allergy, Scientific Advisory Board of the National Eczema Association, and director of the Rady Children's/UC San Diego Eczema and Inflammatory Skin Disease Center. Additionally, he has served in leadership roles on guidelines and consensus statements for multiple dermatological conditions, including acne, rosacea, atopic dermatitis and psoriasis.
Dr. Eichenfield enjoys running, reading, and skiing.
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL
Management of Severe Atopic Dermatitis in Pediatric Patients.
Mancuso JB, Lee SS, Paller AS, Ohya Y, Eichenfield LF
Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric Patients.
Liy-Wong C, Kim M, Kirkorian AY, Eichenfield LF, Diaz LZ, Horev A, Tollefson M, Oranges T, Philips R, Chiu YE, Ghafari G, Arnold JD, Sprague J, Nguyen H, Wan S, Atenafu EG, Pope E, Hamilton J, Naik HB, Lara-Corrales I
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Eichenfield LF, Siegfried E, Kwong P, McBride M, Rieger J, Glover D, Willson C, Davidson M, Burnett P, Olivadoti M
Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
Schachner LA, Andriessen A, Benjamin LT, Claro C, Eichenfield LF, Esposito SM, Keller L, Kircik L, Kwong PC, McCuaig C
Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database.
Levin LE, Shayegan LH, Lucky AW, Hook KP, Bruckner AL, Feinstein JA, Whittier S, Lauren CT, Pope E, Lara-Corrales I, Wiss K, McCuaig CC, Powell J, Eichenfield LF, Levy ML, Diaz L, Glick SA, Paller AS, Price HN, Browning JC, Morel KD
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale.
Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, Krueger J, Harris JE, Dalfonso L, Watkins SE, Crawford JM, ThaÃ§i D, Guttman-Yassky E
Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.
Zaenglein AL, Levy ML, Stefanko NS, Benjamin LT, Bruckner AL, Choate K, Craiglow BG, DiGiovanna JJ, Eichenfield LF, Elias P, Fleckman P, Lawley LP, Lewis RA, Lucky AW, Mathes EF, Milstone LM, Paller AS, Patel SS, Siegel DH, Teng J, Tanumihardjo SA, Thaxton L, Williams ML, PeDRA Use of Retinoids in Ichthyosis Work Group.
Update on pediatric atopic dermatitis.
Tracy A, Bhatti S, Eichenfield LF
Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I).
Janmohamed SR, Grosber M, Eichenfield LF, Ring J, Gutermuth J
Medical algorithm: Treatment of atopic dermatitis in early childhood (part II).
Janmohamed SR, Ring J, Eichenfield LF, Gutermuth J
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, Stein Gold L, Pillai R, Guenin E
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Eichenfield LF, McFalda W, Brabec B, Siegfried E, Kwong P, McBride M, Rieger J, Willson C, Davidson M, Burnett P
Characteristics of nonmelanoma skin cancer in children without identifiable risk factors.
Zhong CS, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Kao PC, London WB, Marghoob AA, Phung TL, Pope E, Skin Cancer in Children and Young Adults Consortium., Eichenfield LF, Huang JT
Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts.
Murrell DF, Lucky AW, Salas-Alanis JC, Woodley DT, Palisson F, Natsuga K, Nikolic M, Ramirez-Quizon M, Paller AS, Lara-Corrales I, Barzegar MA, Sprecher E, Has C, Laimer M, Bruckner AL, Bilgic A, Nanda A, Purvis D, Hovnanian A, Murat-SuÅ¡iÄ‡ S, Bauer J, Kern JS, Bodemer C, Martin LK, Mellerio J, Kowaleski C, Robertson SJ, Bruckner-Tuderman L, Pope E, Marinkovich MP, Tang JY, Su J, Uitto J, Eichenfield LF, Teng J, Aan Koh MJ, Lee SE, Khuu P, Rishel HI, Sommerlund M, Wiss K, Hsu CK, Chiu TW, Martinez AE
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, Pillai R, Guenin E
Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database.
Eichenfield LF, DiBonaventura M, Xenakis J, Lafeuille MH, Duh MS, Fakih I, Levenberg M, Cappelleri JC, Sikirica V
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
Eichenfield LF, Tanghetti EA, Guenin E, Martin G, Pillai R
Isotretinoin and iPledge Program patient information video: A new modality that improves patient comprehension.
Greywal T, Eichenfield LF, Marsch A
Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions.
Schachner LA, Torrelo A, Grada A, Micali G, Kwong PC, Scott GB, Benjamin L, Gonzalez ME, Andriessen A, Eberlein T, Eichenfield LF
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS
Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic.
Reynolds SD, Mathur AN, Chiu YE, Brandling-Bennett HA, Pope E, Siegel MP, Holland KE, Paller AS, Siegfried EC, Tom WL, Lara-Corrales I, Tollefson MM, Maguiness S, Eichenfield LF, Sugarman J, Frieden IJ, Oza VS, Cipriano SD, Huang JT, Shah SD, Lauren CT, Castelo-Soccio L, McMahon P, Cordoro KM
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL
See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.
PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.
Rady Children's updates the Doctor Finder annually. We are not responsible for omissions or errors. Prior to making an appointment, please be sure to check with your health plan to confirm coverage. If you see an error or omission on a physician's profile page, please contact us at firstname.lastname@example.org.